International Journal of Medical Science and Clinical Research Studies

ISSN(print): 2767-8326, ISSN(online): 2767-8342

Volume 04 Issue 03 March 2024

Page No: 363-368

DOI: https://doi.org/10.47191/ijmscrs/v4-i03-01, Impact Factor: 7.949

# Current Approaches in the Management of Monoclonal Gammopathies: an approach to Waldenström Macroglobulinemia

**Isai Gallegos Gomez[1], Jennifer Aida Ortega Romero[2], Daniela Denisse Torreros Lara[3], Rodrigo Garcia Gonzalez[4], Carmen Sabrina Campaña Medina[5], Ariadna Melissa Alonso Padilla[6], Abel Gallegos Aguilar[7], Eotoniel Sanchez Romero[8]**

[1,2,3,4,5,6,7,8]Residente Medicina Interna. Hospital General Regional #1. Instituto Mexicano del Seguro Social. Tijuana, Baja California, México.

**ABSTRACT**

Monoclonal gammopathies encompass a spectrum of disorders characterized by the abnormal proliferation of plasma cells, leading to the production of monoclonal immunoglobulins. Waldenström macroglobulinemia (WM) is a rare, indolent lymphoproliferative disorder characterized by the presence of an IgM monoclonal gammopathy, bone marrow infiltration by lymphoplasmacytic cells, and clinical features such as hyperviscosity, lymphadenopathy, and hepatosplenomegaly. Recent advances in understanding the pathogenesis of WM have led to the development of novel therapeutic strategies, including targeted therapies and immunomodulatory agents, which have significantly improved outcomes for patients. This article provides an overview of the current understanding of WM pathophysiology, clinical presentation, diagnostic approach, and recent advancements in its management.

**KEYWORDS:** Monoclonal, gammopathies, Waldenstrom, cells.

**ARTICLE DETAILS**

**Published On:**
**01 March 2024**

**Available on:**
**https://ijmscr.org/**

## INTRODUCTION

Monoclonal gammopathies are a diverse group of disorders characterized by the clonal proliferation of plasma cells, leading to the production of monoclonal immunoglobulins. These disorders range from benign conditions, such as monoclonal gammopathy of undetermined significance (MGUS), to malignant diseases, such as multiple myeloma and its variants. Monoclonal gammopathies are commonly detected incidentally on routine laboratory testing and can pose a diagnostic and management challenge for clinicians.1,2

The risk of progression from MGUS to symptomatic multiple myeloma or related disorders varies among individuals and is influenced by factors such as the level and type of monoclonal protein, the presence of cytogenetic abnormalities, and the presence of symptoms. Therefore, risk stratification is crucial in determining the appropriate management approach for patients with monoclonal gammopathies.3

In recent years, there have been significant advancements in the understanding of the pathophysiology of monoclonal gammopathies, leading to the development of novel treatment strategies. These include immunomodulatory drugs, proteasome inhibitors, monoclonal antibodies, and targeted therapies. The choice of treatment depends on various factors, including the patient's age, comorbidities, and disease characteristics.4,5

Waldenström macroglobulinemia (WM) is a rare, indolent lymphoproliferative disorder characterized by the presence of an IgM monoclonal gammopathy. First described by Jan Waldenström in 1944, WM represents approximately 1-2% of all hematologic malignancies. The disease primarily affects older individuals, with a median age at diagnosis of around 65-70 years.6

WM is considered a distinct clinicopathologic entity within the spectrum of monoclonal gammopathies, which also includes conditions such as multiple myeloma and monoclonal gammopathy of undetermined significance (MGUS). Unlike multiple myeloma, which is characterized

by the production of monoclonal immunoglobulins other than IgM and often presents with lytic bone lesions, WM is typically associated with the production of IgM monoclonal gammopathy and bone marrow infiltration by lymphoplasmacytic cells without significant lytic bone disease.7,8

The clinical presentation of WM can vary widely, ranging from asymptomatic disease to symptoms related to the presence of the monoclonal protein, such as hyperviscosity syndrome, peripheral neuropathy, and cold agglutinin disease. The diagnosis of WM is based on the presence of IgM monoclonal gammopathy along with evidence of bone marrow involvement by lymphoplasmacytic cells and characteristic clinical features.9

In recent years, there have been significant advancements in the understanding of the pathogenesis of WM, leading to the development of novel therapeutic approaches that have revolutionized the management of this disease. Targeted therapies, such as the Bruton tyrosine kinase (BTK) inhibitor ibrutinib, have shown remarkable efficacy in WM and have become the cornerstone of treatment for many patients. Other agents, such as the proteasome inhibitor bortezomib and the immunomodulatory drug lenalidomide, have also demonstrated activity in WM and are commonly used in clinical practice.10

Despite these advancements, challenges remain in the management of WM, including the development of resistance to targeted therapies and the optimal sequencing of therapies. Ongoing research efforts are focused on addressing these challenges and further improving outcomes for patients with WM.11

This article provides a comprehensive review of the current understanding of the diagnosis and management of WM, with a focus on recent advancements and future directions in the field.

**RELEVANCE**

It is essential to consider the investigation and management of these conditions, including the principles of management and therapeutic implications. The complexity and heterogeneity of monoclonal immunoglobulin-associated renal diseases, as well as the need for a term that conveys the pathologic nature of these diseases, are also crucial aspects to consider. Additionally, the evolving immunologic perspectives in chronic inflammatory demyelinating polyneuropathy and the investigation and management of the monoclonal gammopathy of undetermined significance are relevant in understanding the broader spectrum of monoclonal gammopathies and their associated complications.12,13,14

Furthermore, the successful use of lenalidomide to treat refractory acquired von Willebrand disease associated with monoclonal gammopathy and the thrombotic microangiopathy associated with monoclonal gammopathy highlight the therapeutic implications and challenges in managing these conditions. Additionally, the evolving use of serum free light chain assays in hematology provides insights into the advancements in diagnostic tools for monoclonal gammopathies, which is crucial in the context of modern therapies.13,14,15

**DIAGNOSIS METHODS**

Based on the analysis of the available literature, the diagnosis for an article on the approach to monoclonal gammopathies with a focus on modern therapies can be summarized as follows. Monoclonal gammopathy of undetermined significance (MGUS) is a common condition, particularly in the elderly. It is crucial to understand the pathologic nature of these diseases, as there is a need for a term that properly conveys their significance. The association between monoclonal gammopathy and various clinical manifestations, such as renal and peripheral nervous system diseases, presents challenges to physicians in terms of intervention and treatment). Additionally, the management of monoclonal gammopathy of renal significance (MGRS) is challenging due to the scarcity of data regarding the management of this rare condition. Furthermore, the clinical relevance and management of MGUS and related disorders are critical, as MGUS is one of the most common pre-malignant disorders.16,17,18

The association between monoclonal gammopathy and various clinical manifestations, such as renal and peripheral nervous system diseases, presents challenges to physicians in terms of intervention and treatment. Additionally, the management of monoclonal gammopathy of renal significance (MGRS) is challenging due to the scarcity of data regarding the management of this rare condition . Furthermore, the clinical relevance and management of MGUS and related disorders are critical, as MGUS is one of the most common pre-malignant disorders.19,20

In addition, the association between monoclonal gammopathy and various clinical manifestations, such as renal and peripheral nervous system diseases, presents challenges to physicians in terms of intervention and treatment. Furthermore, the management of monoclonal gammopathy of renal significance (MGRS) is challenging due to the scarcity of data regarding the management of this rare condition. Moreover, the clinical relevance and management of MGUS and related disorders are critical, as MGUS is one of the most common pre-malignant disorders.20,21,22

The diagnosis for an article on the approach to monoclonal gammopathies with a focus on modern therapies should encompass the understanding of the pathologic nature of

these diseases, the challenges in managing associated clinical manifestations, and the critical relevance of MGUS and related disorders in clinical practice.21,22,23

## WALDENSTRÖM MACROGLOBULINEMIA DIAGNOSIS

The diagnosis of Waldenström macroglobulinemia (WM) involves a comprehensive approach that integrates clinical findings, laboratory tests, imaging studies, and bone marrow examination. WM is characterized by the presence of an IgM monoclonal gammopathy along with bone marrow infiltration by lymphoplasmacytic cells.24,25

Clinical Presentation: Patients with WM may present with nonspecific symptoms such as fatigue, weakness, weight loss, and night sweats. Symptoms related to hyperviscosity, such as headache, dizziness, visual disturbances, and bleeding diathesis, may also occur.26

Laboratory Tests: The diagnosis of WM is confirmed by the presence of an IgM monoclonal protein in serum or urine. Serum protein electrophoresis (SPEP) and immunofixation electrophoresis (IFE) are used to detect and characterize the monoclonal protein. Additionally, serum viscosity may be measured to assess for hyperviscosity syndrome.26

Bone Marrow Examination: Bone marrow aspiration and biopsy are essential for confirming the presence of lymphoplasmacytic infiltration. The finding of ≥10% clonal lymphoplasmacytic cells in the bone marrow is consistent with the diagnosis of WM.26

Imaging Studies: Imaging studies, such as skeletal survey, computed tomography (CT) scans, magnetic resonance imaging (MRI), and positron emission tomography (PET) scans, may be performed to evaluate for lytic bone lesions, lymphadenopathy, and organomegaly.26

Flow Cytometry: Flow cytometry of the bone marrow can help identify the phenotype of the abnormal lymphoplasmacytic cells, confirming their clonality.26

Genetic Testing: Fluorescence in situ hybridization (FISH) and cytogenetic analysis can identify chromosomal abnormalities, such as deletion of chromosome 6q or trisomy 4, which are commonly associated with WM.26

To diagnose and manage Waldenström macroglobulinemia (WM), several diagnostic advances have been made. The diagnostic screening panels traditionally include protein electrophoresis and immunofixation electrophoresis of serum and urine. The consensus diagnostic criteria for WM were presented at the Second International Workshop in 2002. Currently, the recommended panel for diagnostic screening includes serum protein electrophoresis, immunofixation electrophoresis, and free light chain quantitation. Additionally, the detection of the MYD88 (L265P) somatic mutation in the cerebrospinal fluid has proven useful for the diagnosis and monitoring of central nervous system involvement in WM. Furthermore, the presence of IgM monoclonal protein associated with ≥10% clonal lymphoplasmacytic cells in the bone marrow confirms the diagnosis of WM.27,28,29

The differentiation between IgM multiple myeloma and WM is crucial as the approach to therapy differs. Patients with WM should be treated in the setting of a clinical trial if possible. The diagnostic sensitivity of biochemical tests in the screening of monoclonal gammopathy, including WM, has been reported to be high. Moreover, the diagnostic markers LDH, IgM, IgG, IgA, and serum light chain Κ have shown higher diagnostic efficiency in distinguishing WM from other IgM monoclonal gammopathies.30

The diagnostic advances for WM include the consensus diagnostic criteria, recommended screening panels, and the detection of specific somatic mutations. These advancements aid in accurately diagnosing WM and differentiating it from other related conditions, thereby guiding appropriate therapeutic interventions.

## TREATMENT

Based on the provided references, significant advances have been made in the therapeutic approach to Waldenström macroglobulinemia (WM). The management of WM has evolved with the development of novel treatment strategies and the identification of prognostic factors. The International Myeloma Working Group has established criteria for the classification of monoclonal gammopathies, multiple myeloma, and related disorders, providing a framework for understanding the disease spectrum (Kyle et al., 2003). Additionally, the consensus statement on the management of WM patients during the COVID-19 pandemic highlights the importance of adapting treatment recommendations to fit the specific realities associated with the management of WM, ensuring patient safety during challenging times (Talaulikar et al., 2020).31,32

The treatment landscape for WM has been shaped by the recommendations from the Eighth International Workshop on Waldenström's Macroglobulinemia, emphasizing the endorsement of active enrollment in clinical trials whenever possible for most patients with WM. Furthermore, the emergence of novel therapies such as ibrutinib has revolutionized the management of WM. Studies have elucidated the role of BTK in the pathophysiology of WM, leading to the initial investigation and approval of ibrutinib in WM. Moreover, the use of next-generation sequencing has provided valuable molecular and genetic biomarkers that offer treatment insights in clinical practice for WM, addressing the clinical challenges in both diagnosis and treatment.31,32

The therapeutic landscape for WM has also been influenced by clinical trials evaluating the efficacy of different treatment regimens. For instance, the assessment of fixed-duration therapies for treatment-naïve WM patients has provided valuable insights into the management of the disease. Additionally, the prospectively randomized trial of the European Consortium for Waldenström's Macroglobulinemia has demonstrated the significant activity of bortezomib in WM, contributing to the expansion of treatment options for patients.32,33,34

The therapeutic advances in WM have been driven by a comprehensive understanding of the disease spectrum, the development of novel treatment strategies, and the identification of prognostic factors. The evolving treatment landscape, characterized by the endorsement of active enrollment in clinical trials, the emergence of novel therapies such as ibrutinib, and the insights provided by clinical trials, reflects the continuous efforts to improve patient outcomes and quality of life.

## CONCLUSIONS

The therapeutic landscape for Waldenström macroglobulinemia (WM) has witnessed significant advancements, driven by a comprehensive understanding of the disease spectrum and the development of novel treatment strategies. The International Myeloma Working Group has played a pivotal role in establishing criteria for the classification of monoclonal gammopathies, multiple myeloma, and related disorders, providing a framework for understanding the disease spectrum . Furthermore, the consensus statement on the management of WM patients during the COVID-19 pandemic emphasizes the importance of adapting treatment recommendations to ensure patient safety during challenging times .

The treatment recommendations from the Eighth International Workshop on Waldenström's Macroglobulinemia have endorsed active enrollment in clinical trials whenever possible for most patients with WM, reflecting the evolving treatment landscape and the continuous efforts to improve patient outcomes and quality of life . The emergence of novel therapies such as ibrutinib has revolutionized the management of WM, with studies elucidating the role of BTK in the pathophysiology of WM, leading to the initial investigation and approval of ibrutinib in WM .

Moreover, the use of next-generation sequencing has provided valuable molecular and genetic biomarkers that offer treatment insights in clinical practice for WM, addressing the clinical challenges in both diagnosis and treatment . Clinical trials evaluating the efficacy of different treatment regimens have also contributed to the expansion of treatment options for WM, with studies assessing fixed-duration therapies for treatment-naïve WM patients providing valuable insights into the management of the disease .

The therapeutic advances in WM have been shaped by the development of novel treatment strategies, the identification of prognostic factors, and the endorsement of active enrollment in clinical trials, reflecting the continuous efforts to improve patient outcomes and quality of life.

## REFERENCES


I. (2009). Screening panels for detection of monoclonal gammopathies. clinical chemistry, 55(8), 1517-1522. https://doi.org/10.1373/clinchem.2009.126664
II. (2016). Laboratory testing requirements for diagnosis and follow-up of multiple myeloma and related plasma cell dyscrasias. clinical chemistry and laboratory medicine (cclm), 54(6). https://doi.org/10.1515/cclm-2015-0580
III. (2004). Lymphoma and peripheral neuropathy: a clinical review. muscle & nerve, 31(3), 301-313. https://doi.org/10.1002/mus.20163
IV. (2013). Recognizing nodal marginal zone lymphoma: recent advances and pitfalls. a systematic review. haematologica, 98(7), 1003-1013. https://doi.org/10.3324/haematol.2012.083386
V. (2011). Temporal and geographic variations of waldenstrom macroglobulinemia incidence. cancer, 118(15), 3793-3800. https://doi.org/10.1002/cncr.26627
VI. (2010). Diagnosis and management of waldenström macroglobulinemia: mayo stratification of macroglobulinemia and risk-adapted therapy (msmart) guidelines. mayo clinic proceedings, 85(9), 824-833. https://doi.org/10.4065/mcp.2010.0304
VII. (2005). Diagnosis and management of waldenstrom's macroglobulinemia. journal of clinical oncology, 23(7), 1564-1577. https://doi.org/10.1200/jco.2005.03.144
VIII. (2017). Diagnosis and management of waldenström macroglobulinemia. jama oncology, 3(9), 1257. https://doi.org/10.1001/jamaoncol.2016.5763
IX. (2017). Bing-neel syndrome: illustrative cases and comprehensive review of the literature. mediterranean journal of hematology and infectious diseases, 9(1), e2017061. https://doi.org/10.4084/mjhid.2017.061
X. (2016). Optimizing therapy for nodal marginal zone lymphoma. blood, 127(17), 2064-2071. https://doi.org/10.1182/blood-2015-12-624296
XI. (2010). Igm multiple myeloma: disease definition, prognosis, and differentiation from waldenstrom's

macroglobulinemia. american journal of hematology, 85(11), 853-855. https://doi.org/10.1002/ajh.21845

XII. (2017). Monoclonal igm gammopathy and waldenström's macroglobulinemia. deutsches ärzteblatt international. https://doi.org/10.3238/arztebl.2017.0745

XIII. (2006). Monoclonal gammopathy of undetermined significance, waldenström macroglobulinemia, al amyloidosis, and related plasma cell disorders: diagnosis and treatment. mayo clinic proceedings, 81(5), 693-703. https://doi.org/10.4065/81.5.693

XIV. (2005). Prognostic validation of the international classification of immunoglobulin m gammopathies: a survival advantage for patients with immunoglobulin m monoclonal gammopathy of undetermined significance?. clinical cancer research, 11(5), 1786-1790. https://doi.org/10.1158/1078-0432.ccr-04-1899

XV. (1995). Pathogenesis and therapy of neuropathies associated with monoclonal gammopathies. annals of neurology, 37(S1), 32-42. https://doi.org/10.1002/ana.410370705

XVI. (2022). Diagnostics in waldenström's macroglobulinemia: a consensus statement of the european consortium for waldenström's macroglobulinemia. leukemia, 37(2), 388-395. https://doi.org/10.1038/s41375-022-01762-3

XVII. (2020). Younger patients with waldenström macroglobulinemia exhibit low risk profile and excellent outcomes in the era of immunotherapy and targeted therapies. american journal of hematology, 95(12), 1473-1478. https://doi.org/10.1002/ajh.25961

XVIII. (2005). Lymphoplasmacytic lymphoma/ waldenstrom macroglobulinemia. advances in anatomic pathology, 12(5), 246-255. https://doi.org/10.1097/01.pap.0000184176.65919.17

XIX. (2018). Serum markers in the differential diagnosis of waldenstrom macroglobulinemia and other igm monoclonal gammopathies. journal of clinical laboratory analysis, 33(3). https://doi.org/10.1002/jcla.22827

XX. (2018). Kidney involvement of patients with waldenström macroglobulinemia and other igm-producing b cell lymphoproliferative disorders. clinical journal of the american society of nephrology, 13(7), 1037-1046. https://doi.org/10.2215/cjn.13041117

XXI. (2005). Immunoglobulin m monoclonal gammopathies of undetermined significance and indolent waldenström's macroglobulinemia recognize the same determinants of evolution into symptomatic lymphoid disorders: proposal for a common prognostic scoring system. journal of clinical oncology, 23(21), 4662-4668. https://doi.org/10.1200/jco.2005.06.147

XXII. (2023). Waldenström macroglobulinemia: 2023 update on diagnosis, risk stratification, and management. american journal of hematology, 98(2), 348-358. https://doi.org/10.1002/ajh.26796

XXIII. (2023). Comparision of the diagnostic sensitivity of biochemical tests in the screening of monoclonal gammopathy. international journal of clinical biochemistry and research, 10(1), 96-100. https://doi.org/10.18231/j.ijcbr.2023.015

XXIV. (2021). Hyperviscosity-related retinopathy and serous macular detachment in waldenström's macroglobulinemia: a mortal case in 5 years. european journal of ophthalmology, 32(4), NP109-NP114. https://doi.org/10.1177/11206721211002066

XXV. (2023). Diagnosing, imaging, and successfully treating a debilitating case of bing–neel syndrome: a multidisciplinary feat. clinical case reports, 11(5). https://doi.org/10.1002/ccr3.7296

XXVI. (2023). Marginal zone lymphoma: 2023 update on diagnosis and management. american journal of hematology, 98(10), 1645-1657. https://doi.org/10.1002/ajh.27058

XXVII. (2020). A rare case of synchronous waldenström's macroglobulinemia and cutaneous squamous cell carcinoma with a lung mass: a diagnostic and management dilemma. case reports in oncology, 13(3), 1474-1482. https://doi.org/10.1159/000511460

XXVIII. (2002). Cast nephropathy in a case of waldenström's macroglobulinemia. nephron, 91(3), 512-515. https://doi.org/10.1159/000064299

XXIX. [29] (2019). An unusual presentation of a rare neoplasm - waldenstrom's macroglobulinemia. tropical journal of pathology and microbiology, 5(10), 822-826. https://doi.org/10.17511/jopm.2019.i10.11

XXX. (2021). Eha endorsement of esmo clinical practice guidelines for diagnosis, treatment, and follow-up for waldenström's macroglobulinemia. hemasphere, 5(10), e634. https://doi.org/10.1097/hs9.0000000000000634

XXXI. (2023). Waldenström macroglobulinemia: diagnosis and treatment. hematologia. https://doi.org/10.5603/hcp.a2022.0014

XXXII. (2009). Simultaneously significant hepatic and mild splenic uptake of tc-99m mdp resulting from waldenstrom macroglobulinemia. clinical nuclear medicine, 34(7), 441-442. https://doi.org/10.1097/rlu.0b013e3181a7d0a3

XXXIII. (2017). Diffuse large b-cell lymphoma mimicking cardiac amyloidosis. clinical case reports, 5(6), 1034-1035. https://doi.org/10.1002/ccr3.948

XXXIV. (2014). A paroxysmal nocturnal haemoglobinuria progress with waldenström macroglobulinemia along with t cell monoclonal expansion. indian journal of hematology and blood transfusion, 30(S1), 227-231. https://doi.org/10.1007/s12288-014-0337-9